Arcutis Biotherapeutics, Inc. — Director's Dealing 2022

Aug 5, 2022

SEC Form 4/A — Form 4/A

Issuer: Arcutis Biotherapeutics, Inc. (ARQT)
CIK: 0001787306
Period of Report: 2022-03-23

Reporting Person: Turney Patricia A. (SVP, Operations)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2022-03-23	Common Stock	M	15331	$6.52	Acquired	46444	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2022-03-23	Stock Option (Right to Buy)	$6.52	M	15331	Disposed	2029-11-20	Common Stock (15331)	Direct

Footnotes

F1: Includes 24,925 restricted stock units.

F2: The option vests as to 1/4 of the total shares on November 14, 2020, and then 1/48 of the total shares vest monthly thereafter, with 100% of the total shares vested and exercisable on November 14, 2023, subject to the Reporting Person's provision of service to the Issuer on each vesting date. The option contains an early-exercise provision and is exercisable as to unvested shares, subject to the Issuer's right of repurchase.